National Pension Service Has $62.69 Million Position in Eli Lilly and Company (LLY)
National Pension Service lifted its position in Eli Lilly and Company (NYSE:LLY) by 12.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 758,088 shares of the company’s stock after buying an additional 82,222 shares during the quarter. National Pension Service owned about 0.07% of Eli Lilly and worth $62,694,000 as of its most recent SEC filing.
Several other large investors have also recently added to or reduced their stakes in the stock. Heritage Trust Co bought a new position in Eli Lilly and during the first quarter worth $135,000. Point72 Asia Hong Kong Ltd boosted its position in Eli Lilly and by 237.4% during the first quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock worth $148,000 after purchasing an additional 1,239 shares during the period. Penserra Capital Management LLC boosted its position in Eli Lilly and by 9.5% during the first quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock worth $170,000 after purchasing an additional 176 shares during the period. American National Bank boosted its position in Eli Lilly and by 5.2% during the second quarter. American National Bank now owns 2,088 shares of the company’s stock worth $172,000 after purchasing an additional 104 shares during the period. Finally, Sandy Spring Bank boosted its position in Eli Lilly and by 51.8% during the first quarter. Sandy Spring Bank now owns 2,198 shares of the company’s stock worth $185,000 after purchasing an additional 750 shares during the period. 75.72% of the stock is owned by institutional investors and hedge funds.
A number of equities analysts have commented on LLY shares. UBS AG cut shares of Eli Lilly and to a “hold” rating and set a $85.00 price objective for the company. in a research report on Wednesday, July 26th. Jefferies Group LLC reaffirmed a “buy” rating and set a $93.00 price objective on shares of Eli Lilly and in a research report on Thursday, June 22nd. Berenberg Bank reaffirmed a “buy” rating and set a $98.00 price objective on shares of Eli Lilly and in a research report on Friday, August 4th. Zacks Investment Research raised shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 price objective for the company in a research report on Monday, July 17th. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and set a $105.00 price objective (up from $103.00) on shares of Eli Lilly and in a research report on Friday, September 8th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $88.27.
Eli Lilly and Company (NYSE:LLY) traded up 0.70% on Friday, reaching $83.91. The company had a trading volume of 3,148,723 shares. Eli Lilly and Company has a 12-month low of $64.18 and a 12-month high of $86.72. The stock’s 50-day moving average price is $80.84 and its 200-day moving average price is $82.02. The stock has a market capitalization of $88.53 billion, a P/E ratio of 36.31 and a beta of 0.34.
Eli Lilly and (NYSE:LLY) last issued its earnings results on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, topping the consensus estimate of $1.05 by $0.06. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The business had revenue of $5.82 billion during the quarter, compared to the consensus estimate of $5.60 billion. During the same quarter last year, the company earned $0.86 EPS. The firm’s revenue was up 7.8% compared to the same quarter last year. On average, equities research analysts anticipate that Eli Lilly and Company will post $4.16 EPS for the current fiscal year.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 180,000 shares of the firm’s stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $81.06, for a total value of $14,590,800.00. Following the completion of the transaction, the insider now owns 123,865,804 shares in the company, valued at approximately $10,040,562,072.24. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In the last 90 days, insiders sold 590,000 shares of company stock valued at $48,551,300. 0.20% of the stock is owned by corporate insiders.
WARNING: This report was published by Watch List News and is owned by of Watch List News. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://www.watchlistnews.com/national-pension-service-has-62-69-million-position-in-eli-lilly-and-company-lly/1585472.html.
Eli Lilly and Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.